TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04342351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perindopril
Description: Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test
Description: All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test
Description: All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
Study: NCT01006876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
Study: NCT00863343

Intervention type: BIOLOGICAL
Intervention: Public Health Notification
Description: For any H5 positive results, notification of the result to the site's local public health authorities.
Study: NCT02649439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC -V
Description: Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC -V
Description: Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
Study: NCT03267134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Device implanted into the Schlemm's canal of the eye for the purpose of providing a natural outflow pathway for aqueous humor. The Hydrus Microstent is intended for lifetime use of the glaucoma patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmic surgery
Description: Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
Study: NCT00282113

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ProBioPlus
Description: ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culturelle
Description: Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
Study: NCT02276989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.~On Day 1, pregabalin PK measures will be collected.~On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.~On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On the mornings of Days 7-8 subjects will receive their PGB dose only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine
Description: On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.~On Day 11, PK testing of QUIN and PGB will be repeated.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.~On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: All subjects will receive riboflavin on the following days of the study:~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
Study: NCT01262157

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Vascuspec)
Description: Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity shock wave therapy
Description: Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
Study: NCT02189343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215 in combination with pomalidomide and dexamethasone
Description: Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
Study: NCT04281758

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage
Description: 16 oz (473.2 ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage
Description: 16 oz (473.2 ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage
Description: 16 oz (473.2 ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage
Description: 16 oz (473.2 ml)
Study: NCT02084108

Intervention type: OTHER
Group type: OTHER
Intervention: intervention
Description: intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
Study: NCT01656135

Intervention type: OTHER
Group type: OTHER
Intervention: Blood drawing for immune monitoring and questionnaires
Study: NCT02027545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Education
Description: Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider Education
Description: Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
Study: NCT00208156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study: NCT02770183

Intervention type: DEVICE
Intervention: Imacor
Description: In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.~During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive.
Study: NCT00784212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02827903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Rosuvastatin
Description: Group I: Metformin + Rosuvastatin,
Study: NCT01328301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
Study: NCT02027545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance Measure Modification
Description: The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Performance Measure Modification
Description: The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simple Informational Booklet
Description: A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
Study: NCT01962766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Myofunctionnal therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instructions
Study: NCT04075682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inserts with efficacy messages
Description: Four rotating inserts (i.e., small, printed messages) with messages about cessation benefits (i.e., response efficacy) and tips to quit (i.e., self-efficacy messages) will be placed inside cigarette packs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inserts with efficacy messages
Description: Four rotating inserts (i.e., small, printed messages) with messages about cessation benefits (i.e., response efficacy) and tips to quit (i.e., self-efficacy messages) will be placed inside cigarette packs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictorial warnings on packs
Description: Four rotating pictorial warnings illustrating the harms of smoking will be printed on labels that will placed on and cover approximately 50% of the cigarette packs.
Study: NCT02827903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin + placebo
Description: Group II: Metformin + placebo,
Study: NCT04075682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictorial warnings on packs
Description: Four rotating pictorial warnings illustrating the harms of smoking will be printed on labels that will placed on and cover approximately 50% of the cigarette packs.
Study: NCT03910205

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Enzim linked immunoabsorbant assay

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Enzim linked immunoabsorbant assay

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Enzim linked immunoabsorbant assay

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Enzim linked immunoabsorbant assay
Study: NCT03217383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MATRx plus
Description: The MATRx plus test is a 2- or 3-night home sleep test that uses temporary titration trays to move the lower jaw in response to respiratory events. The purpose of the test is to predict oral appliance therapy outcome, and to provide a protrusive position for individuals predicted to experience therapeutic success.
Study: NCT00331669

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: deep brain stimulation
Description: high frequency stimulation
Study: NCT01118793

Intervention type: DRUG
Intervention: Clopidogrel
Description: 150 mg dosage of Clopidogrel for 7 to 10 days.
Study: NCT02827903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo + Rosuvastatin
Description: Group III: placebo + Rosuvastatin
Study: NCT00937469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills training, parental tr. and standard tr.
Description: Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
Study: NCT00776438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion, influenza vaccine
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion, influenza vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03296410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 and two measles attenuated live vaccine
Description: infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 and attenuated Japanese encephalitis vaccine
Description: infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: two measles attenuated live vaccine
Description: infants vaccined with one dose two measles attenuated live vaccine at 8 months old.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: live attenuated Japanese encephalitis vaccine
Description: infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 vaccine
Description: infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
Study: NCT01832792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face self-help
Description: Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-mail self-help
Description: Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List
Description: Waiting list condition - participants assigned to a waiting list (no intervention) condition
Study: NCT05127083

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Patients will be treated with localized PBM with a diode laser
Description: Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be treated with localized PBM with a diode laser
Description: Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Patients will be treated with localized PBM with a diode laser
Description: Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
Study: NCT04485247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transumbilical Laparoscopic-Assisted Appendectomy
Description: appendectomy performed extracorporeally through umbilical port

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-port laparoscopic appendectomy
Description: appendectomy performed intracorporeally with 3-port
Study: NCT01328301

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speed-stable treadmill training
Description: Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
Study: NCT00281619

Intervention type: DRUG
Intervention: CellCept (mycophenolate mofetil)

Intervention type: BEHAVIORAL
Intervention: Dietary Monitoring

Intervention type: BEHAVIORAL
Intervention: Drug Diary

Intervention type: PROCEDURE
Intervention: Blood Sampling
Study: NCT00832078

Intervention type: DEVICE
Group type: OTHER
Intervention: SpeediCath Compact Male
Description: CH 12 hydrophilic coated intermitten compact catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: SpeediCath Compact Male
Description: CH 12 hydrophilic coated intermitten compact catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Speedicath
Description: CH 12 hydrophilic coated intermittent coated catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Speedicath
Description: CH 12 hydrophilic coated intermittent coated catheter
Study: NCT00996866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
Study: NCT02304731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Incremental running
Study: NCT01307904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Each healthy and Diabetic volunteers received 50 grams of glucose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dates
Description: Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
Study: NCT03612609

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood, urine and semen sample
Description: Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 15, 30, 60 and 90 days after. Dengue virus RNA being diagnosed with blood and/or urine sample positive for dengue virus RNA. Dengue virus RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
Study: NCT01312883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral education intervention
Description: One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
Study: NCT01692925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.